Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 4, 2016
app pub date -
Nov 13, 2015
filing date -
Nov 13, 2015
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
This invention describes a new type of covalent-network ternary inorganic metal sulfide compounds M1M2S4 (M1, independently, is, Mg, Ca, Mn, Fe, or Zn; M2=Mo or W) and a process for preparing the biocompatible nanoparticles of such compounds. The nanoparticles are surface-modified with a capping agent and/or a biocompatible polymer and have the size from a few nanometers to several thousand nanometers. These nanoparticles are nontoxic and can be internalized by cells to deplete copper ions via a highly selective ion-exchange reaction between the intracellular copper ions and the divalent ion bound in the nanoparticles for the application of inhibiting angiogenesis in cancer and other diseases.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully